Cerus Corp.
Cerus (Nasdaq: CERS) is a biomedical products company that develops and commercializes the INTERCEPT Blood System, designed to reduce pathogens in donated blood components for transfusion. Its products treat platelets and plasma, and its cryoprecipitation system uses treated plasma to produce INTERCEPT Fibrinogen… From the company’s description.
Over the twelve months to Sep 30, 2026, Cerus Corp. reported revenue of $233.40M, up 3.3% from a year earlier, and a net loss of $7.39M. Its operating margin was −1.1%, and operations generated $3.50M in cash. In fiscal 2025, it reported revenue of $233.80M, up 16.1% from fiscal 2024, and a net loss of $15.64M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cerus Corp. does
In the company’s own words
Cerus (Nasdaq: CERS) is a biomedical products company that develops and commercializes the INTERCEPT Blood System, designed to reduce pathogens in donated blood components for transfusion. Its products treat platelets and plasma, and its cryoprecipitation system uses treated plasma to produce INTERCEPT Fibrinogen Complex for bleeding associated with fibrinogen deficiency and pathogen-reduced, cryoprecipitate-reduced plasma. Customers include blood collection centers and transfusion services, which supply hospitals and other providers; sales are made directly and through distributors in the United States and international markets. Cerus also develops a red blood cell system, which is not yet commercialized, and sells an LED-based illuminator in some markets. The company’s technology combines proprietary compounds with processing kits and illuminators to inactivate pathogens in blood components. Cerus reports its operations as one business segment. Its platelet and plasma products are marketed in the United States and multiple international regions, while the cryoprecipitation system is FDA-approved. For fiscal 2025, the company reported total revenue of $ million. Its website is www.cerus.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- CONCORD, CA
- Fiscal year end
- December
- CIK
- 1020214
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cerus Corp. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cerus Corp.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cerus Corp. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cerus Corp.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cerus Corp.'s last four quarterly filings that the numbers alone won't show?”